X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with ALEMBIC LTD - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs ALEMBIC LTD - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

ALEMBIC LTD 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA ALEMBIC LTD TORRENT PHARMA/
ALEMBIC LTD
 
P/E (TTM) x 27.8 122.0 22.8% View Chart
P/BV x 5.3 4.5 116.5% View Chart
Dividend Yield % 1.0 0.2 416.6%  

Financials

 TORRENT PHARMA   ALEMBIC LTD
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-17
ALEMBIC LTD
Mar-16
TORRENT PHARMA/
ALEMBIC LTD
5-Yr Chart
Click to enlarge
High Rs1,76853 3,348.1%   
Low Rs1,18629 4,046.4%   
Sales per share (Unadj.) Rs346.14.7 7,333.4%  
Earnings per share (Unadj.) Rs55.28.8 628.8%  
Cash flow per share (Unadj.) Rs73.39.0 814.2%  
Dividends per share (Unadj.) Rs14.000.15 9,333.3%  
Dividend yield (eoy) %0.90.4 259.5%  
Book value per share (Unadj.) Rs257.127.7 927.2%  
Shares outstanding (eoy) m169.22267.03 63.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.38.7 49.1%   
Avg P/E ratio x26.84.7 572.1%  
P/CF ratio (eoy) x20.14.6 441.8%  
Price / Book Value ratio x5.71.5 388.0%  
Dividend payout %25.41.7 1,484.3%   
Avg Mkt Cap Rs m249,88710,962 2,279.7%   
No. of employees `00011.8NA-   
Total wages/salary Rs m9,934238 4,174.0%   
Avg. sales/employee Rs Th4,971.5NM-  
Avg. wages/employee Rs Th843.2NM-  
Avg. net profit/employee Rs Th792.4NM-  
INCOME DATA
Net Sales Rs m58,5691,260 4,647.2%  
Other income Rs m2,233264 846.5%   
Total revenues Rs m60,8021,524 3,989.4%   
Gross profit Rs m13,77383 16,633.7%  
Depreciation Rs m3,06961 4,998.7%   
Interest Rs m2,0560 685,200.0%   
Profit before tax Rs m10,881285 3,819.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m02,096 0.0%   
Extraordinary Inc (Exp) Rs m0-32 0.0%   
Tax Rs m1,5456 25,329.5%   
Profit after tax Rs m9,3362,343 398.5%  
Gross profit margin %23.56.6 357.9%  
Effective tax rate %14.22.1 663.2%   
Net profit margin %15.9185.9 8.6%  
BALANCE SHEET DATA
Current assets Rs m53,8411,689 3,188.1%   
Current liabilities Rs m31,612486 6,501.8%   
Net working cap to sales %38.095.4 39.8%  
Current ratio x1.73.5 49.0%  
Inventory Days Days97217 44.8%  
Debtors Days Days8481 103.4%  
Net fixed assets Rs m42,0791,624 2,590.9%   
Share capital Rs m846534 158.4%   
"Free" reserves Rs m42,6555,960 715.7%   
Net worth Rs m43,5017,404 587.5%   
Long term debt Rs m22,408104 21,484.5%   
Total assets Rs m101,2508,010 1,264.0%  
Interest coverage x6.3950.7 0.7%   
Debt to equity ratio x0.50 3,656.6%  
Sales to assets ratio x0.60.2 367.7%   
Return on assets %11.329.3 38.5%  
Return on equity %21.531.6 67.8%  
Return on capital %19.631.3 62.7%  
Exports to sales %02.9 0.0%   
Imports to sales %028.9 0.0%   
Exports (fob) Rs mNA37 0.0%   
Imports (cif) Rs mNA364 0.0%   
Fx inflow Rs m20,06637 54,087.3%   
Fx outflow Rs m5,304365 1,453.4%   
Net fx Rs m14,762-328 -4,502.9%   
CASH FLOW
From Operations Rs m10,127346 2,930.3%  
From Investments Rs m-7,869-48 16,531.7%  
From Financial Activity Rs m-1,918-301 637.2%  
Net Cashflow Rs m212-3 -7,050.0%  

Share Holding

Indian Promoters % 71.5 64.0 111.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 0.2 3,510.0%  
FIIs % 12.6 9.7 129.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 26.1 33.7%  
Shareholders   26,511 54,701 48.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  CADILA HEALTHCARE  NOVARTIS  PANACEA BIOTECH  

Compare TORRENT PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Of Mr Modi Providing Impetus to Defense Industry and Key Stocks in Action Today(Pre-Open)

Addressing the Uttar Pradesh Investors Summit, Mr. Modi announced the creation of a defense industrial corridor in Bundelkhand.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Feb 21, 2018 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 8-QTR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS